Supportive care in pediatric acute myeloid leukemia:Expert-based recommendations of the NOPHO-DB-SHIP consortium

References

• Tierens A, Bjørklund E, Siitonen S, et al. Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO-AML 2004 study. Br J Haematol. 2016;174(4):600–609.
   PubMed Web of Science ®Google Scholar
• Rasche M, Zimmermann M, Borschel L, et al. Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. Leukemia [Internet]. 2018;32(10):2167–2177.
   PubMed Web of Science ®Google Scholar
• Aplenc R, Meshinchi S, Sung L, et al. Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the children’s oncology group. Haematologica. 2020;105(7):1879–1886.
   PubMed Web of Science ®Google Scholar
• Klein K, de Haas V, Kaspers GJL. Clinical challenges in de novo pediatric acute myeloid leukemia. Expert Rev Anticancer Ther [Internet]. 2018;18(3):277–293.
   PubMed Web of Science ®Google Scholar
• Creutzig U, Zimmermann M, Reinhardt D, et al. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol. 2004;22(21):4384–4393.
   PubMed Web of Science ®Google Scholar
• Knops RRG, van Dalen EC, Mulder RL, et al. The volume effect in paediatric oncology: a systematic review. Ann Oncol [Internet]. 2013;24(7):1749–1753.
   PubMed Web of Science ®Google Scholar
• Miller TP, Getz KD, Kavcic M, et al. A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the children’s oncology group. Leuk Lymphoma. 2016;57(7):1567–1574.
   PubMed Web of Science ®Google Scholar
• Getz KD, Miller TP, Seif AE, et al. A comparison of resource utilization following chemotherapy for acute myeloid leukemia in children discharged versus children that remain hospitalized during neutropenia. Cancer Med. 2015;4(9):1356–1364.
   PubMed Web of Science ®Google Scholar
• Klein K, van Litsenburg RRL, de Haas V, et al. Causes of early death and treatment-related death in newly diagnosed pediatric acute myeloid leukemia: recent experiences of the Dutch childhood oncology group. Pediatr Blood Cancer. 2020;67(4):e28099.
   PubMed Web of Science ®Google Scholar
• Çiftçiler R, Haznedaroğlu İC, Sayınalp N, et al. The impact of early versus late platelet and neutrophil recovery after induction chemotherapy on survival outcomes of patients with acute myeloid leukemia. Turkish J Hematol. 2020;37:116–120.
   PubMed Web of Science ®Google Scholar
• Walter RB, Kantarjian HM, Huang X, et al. Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson cancer center study. J Clin Oncol. 2010;28(10):1766–1771.
   PubMed Web of Science ®Google Scholar
• Pommert L, Cooper TM, Gerbing RB, et al. Blood count recovery following induction therapy for acute myeloid leukemia in children does not predict survival. Cancers (Basel). 2022;14(3):616.
   PubMed Web of Science ®Google Scholar
• Abla O, Angelini P, Di Giuseppe G, et al. Early complications of hyperleukocytosis and leukapheresis in childhood acute leukemias. J Pediatr Hematol Oncol. 2016;38:111–117.
   PubMed Web of Science ®Google Scholar
• Zeller B, Glosli H, Forestier E, et al. Hyperleucocytosis in paediatric acute myeloid leukaemia - the challenge of white blood cell counts above 200 × 109/l. The NOPHO experience 1984-2014. Br J Haematol. 2017;178(3):448–456.
   PubMed Web of Science ®Google Scholar
• Inaba H, Fan Y, Pounds S, et al. Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis. Cancer. 2008;113(3):522–529.
   PubMed Web of Science ®Google Scholar
• Creutzig U, Rössig C, Dworzak M, et al. Exchange transfusion and leukapheresis in pediatric patients with AML with high risk of early death by bleeding and Leukostasis. Pediatr Blood Cancer. 2016;63(4):640–645.
   PubMed Web of Science ®Google Scholar
• Oberoi S, Lehrnbecher T, Phillips B, et al. Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: a systematic review and meta-analysis. Leuk Res. 2014;38(4):460–468.
   PubMed Web of Science ®Google Scholar
• Shallis RM, Stahl M, Bewersdorf JP, et al. Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits. Expert Rev Hematol. 2020;13(5):489–499.
   PubMed Web of Science ®Google Scholar
• Chen KH, Liu HC, Liang DC, et al. Minimally early morbidity in children with acute myeloid leukemia and hyperleukocytosis treated with prompt chemotherapy without leukapheresis. J Formos Med Assoc. 2014;113(11):833–838.
   PubMed Web of Science ®Google Scholar
• Imamura T, Iwamoto S, Kanai R, et al. Outcome in 146 patients with paediatric acute myeloid leukaemia treated according to the AML99 protocol in the period 2003-06 from the Japan Association of Childhood Leukaemia Study. Br J Haematol. 2012. Internet]. cited 2019 Mar 5;159:204–210. Available from;(2):.
   PubMed Web of Science ®Google Scholar
• Howard SC, Jones DP, Pui C-H. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844–1854.
   PubMed Web of Science ®Google Scholar
• Cheung WL, Hon KL, Fung CM, et al. Tumor lysis syndrome in childhood malignancies. Drugs in Context. 2020;9:1–14.
   Google Scholar
• Jones GL, Will A, Jackson GH, et al. Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. Br J Haematol. 2015;169(5):661–671.
   PubMed Web of Science ®Google Scholar
• Muggia FM, Heinemann HO, Farhangi M, et al. Lysozymuria and renal tubular dysfunction in monocytic and myelomonocytic leukemia. Am J Med. 1969;47(3):351–366.
   PubMed Web of Science ®Google Scholar
• Alakel N, Middeke JM, Schetelig J, et al. Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase. Onco Targets Ther. 2017;10:597–605.
   PubMed Web of Science ®Google Scholar
• Vadhan-raj S, Fayad LE, Fanale MA, et al. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol. 2012;23(6):1640–1645.
   PubMed Web of Science ®Google Scholar
• Feng X, Dong K, Pham D, et al. Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis. J Clin Pharm Ther. 2013;38(4):301–308.
   PubMed Web of Science ®Google Scholar
• Wandt H, Schaefer-Eckart K, Wendelin K, et al. Therapeutic platelet transfusion versus Routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet. 2012;380(9850):1309–1316.
   PubMed Web of Science ®Google Scholar
• Kongstad C, Mikkelsen TS, Hvas AM. Disseminated intravascular coagulation in children with cancer: a systematic review. Pediatr Hematol Oncol. 2020;37(5):390–411.
   PubMed Web of Science ®Google Scholar
• Levi M, Scully M. How I treat disseminated intravascular coagulation. Blood. 2018;131(8):845–854.
   PubMed Web of Science ®Google Scholar
• Monagle P, Cuello CA, Augustine C, et al. American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. Blood Adv. 2018;2(22):3292–3316.
   PubMed Web of Science ®Google Scholar
• Sung L, Lange BJ, Feusner J, et al. Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood. 2007;110(10):3532–3539.
   PubMed Web of Science ®Google Scholar
• Bochennek K, Hassler A, Perner C, et al. Infectious complications in children with acute myeloid leukemia: decreased mortality in multicenter trial AML-BFM 2004. Blood Cancer J. 2016;6(1):e382.
   PubMedGoogle Scholar
• Lehrnbecher T, Varwig D, Kaiser J, et al. Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93. Leukemia. 2004;18(1):72–77.
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52(4):e56–93.
   PubMed Web of Science ®Google Scholar
• Arad-Cohen N, Rowe JM, Shachor-Meyouhas Y. Pharmacological prophylaxis of infection in pediatric acute myeloid leukemia patients. Expert Opin Pharmacother. 2020;21(2):193–205. Internet].;:. Available from.
   PubMed Web of Science ®Google Scholar
• Klein K, Hasle H, Abrahamsson J, et al. Differences in infection prophylaxis measures between paediatric acute myeloid leukaemia study groups within the international Berlin–Frankfürt–Münster (I-BFM) study group. Br J Haematol. 2018;183(1):87–95.
   PubMed Web of Science ®Google Scholar
• van den Bosch C, van Woensel J, van de Wetering MD. Prophylactic antibiotics for preventing gram-positive infections associated with long-term central venous catheters in adults and children receiving treatment for cancer. Cochrane Database Syst Rev. 2021;2021(4). DOI:10.1002/14651858.CD014669
   PubMedGoogle Scholar
• Alexander S, Fisher BT, Gaur AH, et al. Effect of levofloxacin prophylaxis on Bacteremia in children with acute Leukemia or undergoing hematopoietic stem cell transplantation a randomized clinical trial. J Am Med Assoc. 2018;320(10):995–1004.
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Averbuch D, Castagnola E, et al. 8th European Conference on Infections in Leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantation. Lancet Oncol. 2021;22(6):e270–e280.
   PubMed Web of Science ®Google Scholar
• Fisher BT, Robinson PD, Lehrnbecher T, et al. Risk factors for invasive fungal disease in pediatric cancer and hematopoietic stem cell transplantation: a systematic review. J Pediatric Infect Dis Soc. 2018;7(3):191–198.
   PubMed Web of Science ®Google Scholar
• Groll AH, Pana D, Lanternier F, et al. 8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation. Lancet Oncol. 2021;22(6):e254–e269. Internet].;:. Available from
   PubMed Web of Science ®Google Scholar
• Science M, Robinson PD, MacDonald T, et al. Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients. Pediatr Blood Cancer. 2014;61(3):393–400.
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Fisher BT, Phillips B, et al. Clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation recipients. J Clin Oncol. 2020;38(27):3205–3216.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Wei AH. How I treat acute myeloid leukemia in the era of new drugs. Blood. 2020;135(2):85–96.
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Dekker AW, Stamatoullas-Bastard A, et al. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother. 2000;44(7):1887–1893.
   PubMed Web of Science ®Google Scholar
• Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018;36(30):3043–3054.
   PubMed Web of Science ®Google Scholar
• Licciardello M, Pegoraro A, Cesaro S. Prophylaxis and therapy of viral infections in pediatric patients treated for malignancy. Pediatr Rep. 2011;3(1):13–16.
   Google Scholar
• Sandherr M, Hentrich M, von Lilienfeld-Toal M, et al. Antiviral prophylaxis in patients with solid tumours and haematological malignancies—update of the guidelines of the infectious diseases working party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Hematol. 2015;94(9):1441–1450.
   PubMed Web of Science ®Google Scholar
• Haeusler GM, Ammann RA, Carlesse F, et al. SARS-CoV-2 in children with cancer or after haematopoietic stem cell transplant: an analysis of 131 patients. Eur J Cancer. 2021;159:78–86.
   PubMed Web of Science ®Google Scholar
• Millen GC, Arnold R, Cazier JB, et al. COVID-19 in children with haematological malignancies. Arch Dis Child. 2022 Feb;107(2):186-188.
   PubMedGoogle Scholar
• Chiotos K, Hayes M, Kimberlin DW, et al. Multicenter interim guidance on use of antivirals for children with coronavirus disease 2019/severe acute respiratory syndrome coronavirus 2. J Pediatric Infect Dis Soc. 2021;10(1):34–48.
   PubMed Web of Science ®Google Scholar
• Schlage S, Lehrnbecher T, Berner R, et al. SARS-CoV-2 in pediatric cancer: a systematic review. Eur J Pediatr. 2022;181(4):1413–1427.
   PubMed Web of Science ®Google Scholar
• Association AM. Tixagevimab and Cilgavimab (Evusheld) for Pre-Exposure Prophylaxis of COVID-19. Med Lett Drugs Ther. 2022;64:384–385.
   Web of Science ®Google Scholar
• Mikulska M, Cesaro S, de Lavallade H, et al. Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19(6):e188–e199. Internet].;:. Available from
   PubMed Web of Science ®Google Scholar
• Maertens J, Cesaro S, Maschmeyer G, et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016;71(9):1–8.
   PubMed Web of Science ®Google Scholar
• Souza L, Gabrilove J, Lu H, et al. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science. 1986;232(80):61–65.
   PubMedGoogle Scholar
• Gurion R, Belnik-Plitman Y, Gafter-Gvili A, et al. Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia. Cochrane Database Syst Rev. 2012 cited 2019 Mar 5]; Available from 2019 Mar 5;Internet. doi:10.1002/14651858.CD008238.pub3
   Web of Science ®Google Scholar
• Creutzig U, Zimmermann M, Lehrnbecher T, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol. 2006;24(27):4499–4506.
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Creutzig U, Zimmermann M, et al. Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia. Blood. 2006;109(3):936–943.
   PubMed Web of Science ®Google Scholar
• Ehlers S, Herbst C, Zimmermann M, et al. Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-Defective G-CSFReceptor isoform iv is associated with a higher incidence of relapse. J Clin Oncol. 2010;28(15):2591–2597.
   PubMed Web of Science ®Google Scholar
• Løhmann DJA, Asdahl PH, Abrahamsson J, et al. Use of granulocyte colony-stimulating factor and risk of relapse in pediatric patients treated for acute myeloid leukemia according to NOPHO-AML 2004 and DB AML-01. Pediatr Blood Cancer. 2019;66(6):e27701.
   PubMed Web of Science ®Google Scholar
• Zhou B, Song T, Feng Y, et al. Clinical outcome of granulocyte transfusion therapy for the treatment of refractory infection in neutropenic patients with hematological diseases. Ann Hematol. 2018;97(11):2061–2070.
   PubMed Web of Science ®Google Scholar
• Borgstedt-Bendixen SE, Abrahamsson J, S-y H, et al. Abdominal complications during treatment for pediatric acute myeloid leukemia. J Pediatr Hematol Oncol. 2021;44(5):220–229.
   PubMed Web of Science ®Google Scholar
• Shafey A, Ethier M-C, Traubici J, et al. Incidence, risk factors, and outcomes of enteritis, typhlitis, and colitis in children with acute leukemia. J Pediatr Hematol Oncol. 2013;35(7):514–517.
   PubMed Web of Science ®Google Scholar
• Micozzi A, Cartoni C, Monaco M, et al. High incidence of infectious gastrointestinal complications observed in patients with acute myeloid leukemia receiving intensive chemotherapy for first induction of remission. Support Care Cancer. 1996;4(4):294–297.
   PubMed Web of Science ®Google Scholar
• Portugal R, Nucci M. Typhlitis (neutropenic enterocolitis) in patients with acute leukemia: a review. Expert Rev Hematol. 2017;10(2):169–174.
   PubMed Web of Science ®Google Scholar
• Rodrigues FG, Dasilva G, Wexner SD. Neutropenic enterocolitis. World Journal of Gastroenterology. 2017;23(1):42–47. Baishideng Publishing Group Co., Limited.
   PubMed Web of Science ®Google Scholar
• Nava T, Ansari M, Dalle JH, et al. Supportive care during pediatric hematopoietic stem cell transplantation: beyond infectious diseases. A report from workshops on supportive care of the Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (E). Bone Marrow Transplantation. 2020;55(6):1126–1136. Internet].;:. Available from
   PubMed Web of Science ®Google Scholar
• Trehan A, Viani K, da Cruz LB, et al. The importance of enteral nutrition to prevent or treat undernutrition in children undergoing treatment for cancer. Pediatr Blood Cancer. 2020;67(S3):1–8.
   Google Scholar
• McGrath KH, Evans V, Yap J. Indications and patterns of use for parenteral nutrition in pediatric oncology. JPEN J Parenter Enteral Nutr. 2020;44(4):632–638.
   PubMed Web of Science ®Google Scholar
• Iijima M, Stall M, Wang L, et al. Changes in body mass index, weight, and height in children with acute myeloid leukemia and the associations with outcome. Blood Adv. 2022;6:2824–2934.
   PubMed Web of Science ®Google Scholar
• Moody KM, Baker RA, Santizo RO, et al. A randomized trial of the effectiveness of the neutropenic diet versus food safety guidelines on infection rate in pediatric oncology patients. Pediatr Blood Cancer. 2018;65(1):1–8.
   Web of Science ®Google Scholar
• Taggart C, Neumann N, Alonso PB, et al. Comparing a neutropenic diet to a food safety-based diet in pediatric patients undergoing hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25(7):1382–1386.
   PubMed Web of Science ®Google Scholar
• Bansal N, Amdani SM, Hutchins KK, et al. Cardiovascular disease in survivors of childhood cancer. Curr Opin Pediatr. 2018;30(5):628–638.
   PubMed Web of Science ®Google Scholar
• Hutchins KK, Siddeek H, Franco VI, et al. Prevention of cardiotoxicity among survivors of childhood cancer. Br J Clin Pharmacol. 2017;83(3):455–465.
   PubMed Web of Science ®Google Scholar
• Creutzig U, Diekamp S, Zimmermann M, et al. Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML. Pediatr Blood Cancer. 2007;48:651–662.
   PubMed Web of Science ®Google Scholar
• Getz KD, Sung L, Ky B, et al. Occurrence of treatment-related cardiotoxicity and its impact on outcomes among children treated in the AAML0531 clinical trial: a report from the children’s oncology group. J Clin Oncol. 2019;37(1):12–21.
   PubMed Web of Science ®Google Scholar
• Oikonomou EK, Kokkinidis DG, Kampaktsis PN, et al. Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis. JAMA Cardiol. 2019;4(10):1007–1018.
   PubMed Web of Science ®Google Scholar
• Curren V, Dham N, Spurney C. DiagnosisPrevention, treatment and surveillance of anthracycline-induced cardiovascular toxicity in pediatric cancer survivors. 2021;2(1):45–60.
   Google Scholar
• Lancet JE, Uy GL, Newell LF, et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021;8(7):e481–e491. Internet].;:. Available from
   PubMed Web of Science ®Google Scholar
• Cooper TM, Absalon MJ, Alonzo TA, et al. Phase I/II study of CPX-351 followed by fludarabine, cytarabine, and granulocyte-colony stimulating factor for children with relapsed acute myeloid leukemia: a report from the children’s oncology group. J Clin Oncol. 2020;38(19):2170–2177.
   PubMed Web of Science ®Google Scholar
• Yi LL, Kerrigan JE, Lin CP, et al. Topoisomerase IIβ-mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 2007;67(18):8839–8846.
   PubMed Web of Science ®Google Scholar
• Tebbi CK, London WB, Friedman D, et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin’s disease. J Clin Oncol. 2007;25(5):493–500.
   PubMed Web of Science ®Google Scholar
• Tebbi CK, Mendenhall NP, London WB, et al. Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the children’s oncology group. Pediatr Blood Cancer. 2012;59(7):1259–1265.
   PubMed Web of Science ®Google Scholar
• Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009;114(10):2051–2059.
   PubMed Web of Science ®Google Scholar
• Asselin BL, Devidas M, Wang C, et al. Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the children’s oncology group (POG 9404). Blood. 2011;118(4):874–883.
   PubMed Web of Science ®Google Scholar
• Chow EJ, Asselin BL, Schwartz CL, et al. Late mortality after dexrazoxane treatment: a report from the children’s oncology group. J Clin Oncol. 2015;33(24):2639–2645.
   PubMed Web of Science ®Google Scholar
• Shaikh F, Dupuis LL, Alexander S, et al. Cardioprotection and second malignant neoplasms associated With dexrazoxane in children receiving anthracycline chemotherapy: a systematic review and meta-Analysis. J Natl Cancer Inst. 2016;108(4):1–11.
   Google Scholar
• Lipshultz SE, Adams MJ, Colan SD, et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation. 2013;128(17):1927–1955.
   PubMed Web of Science ®Google Scholar
• Getz KD, Sung L, Alonzo TA, et al. Effect of dexrazoxane on left ventricular systolic function and treatment outcomes in patients with acute myeloid leukemia: a report from the children’s oncology group. J Clin Oncol Off J Am Soc Clin Oncol. 2020;38(21):2398–2406.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24(18):2917–2931.
   PubMed Web of Science ®Google Scholar
• Wilhelmsson M, Glosli H, Ifversen M, et al. Long-term health outcomes in survivors of childhood AML treated with allogeneic HSCT: a NOPHO–AML study. Bone Marrow Transplantation. 2019;54(5):726–736.
   PubMed Web of Science ®Google Scholar
• Loren AW, Senapati S. Fertility preservation in patients with hematologic malignancies and recipients of hematopoietic cell transplants. Blood. 2019;134(9):746–760.
   PubMed Web of Science ®Google Scholar
• Salama M, Anazodo A, Woodruff TK. Preserving fertility in female patients with hematological malignancies: a multidisciplinary oncofertility approach. Ann Oncol. 2019;30(11):1760–1775.
   PubMed Web of Science ®Google Scholar
• Joshi S, Savani BN, Chow EJ, et al. Clinical guide to fertility preservation in hematopoietic cell transplant recipients. Bone Marrow Transplantation. 2014;49(4):477–484.
   PubMed Web of Science ®Google Scholar
• Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36(19):1994–2001.
   PubMed Web of Science ®Google Scholar
• Molgaard-Hansen L, Skou A-S, Juul A, et al. Pubertal development and fertility in survivors of childhood acute myeloid leukemia treated with chemotherapy only: a NOPHO-AML study. Pediatr Blood Cancer. 2013;60(12):1988–1995.
   PubMed Web of Science ®Google Scholar
• Borgström B, Fridström M, Gustafsson B, et al. A prospective study on the long-term outcome of prepubertal and pubertal boys undergoing testicular biopsy for fertility preservation prior to hematologic stem cell transplantation. Pediatr Blood Cancer. 2020;67(9):1–11.
   Web of Science ®Google Scholar